Navigation Links
Pharmatech 2.0: Introducing Pharmatech Oncology
Date:1/5/2009

DENVER, Jan. 5 /PRNewswire/ -- Pharmatech, Inc. announces the launch of a new campaign, Pharmatech 2.0, to highlight the company's focus in oncology, along with other key company developments that will take place in early January 2009. The next generation of Pharmatech will feature a name change from Pharmatech, Inc. to Pharmatech Oncology, Inc., as well as a new web site and emerging roles and responsibilities of the executive leadership team.

With the start of 2009, all business will be managed under the name Pharmatech Oncology, Inc. The Pharmatech Board of Directors implemented the name change from the parent company of Pharmatech, Inc. to the subsidiary name of Pharmatech Oncology. Anders Malm, current President, states, "There was a need in the marketplace for better recognition of what type of business Pharmatech was involved in. Changing from Pharmatech to Pharmatech Oncology relays a core understanding that Pharmatech works within the cancer arena."

The leadership team at Pharmatech Oncology will also be undergoing a transformation in roles and titles. Current Chief Executive Officer, Matthew B. Wiener, PharmD, will now take over the daily business operations under the title Chairman and Chief Operating Officer. Anders Malm, current President, will now replace Dr. Wiener as CEO. Pharmatech Oncology also welcomes Rob Bohacs as the new Corporate Development Manager.

Pharmatech Oncology will also introduce a new web site, http://www.pharmatechoncology.com. The launch of the new web site will showcase a more functional format, along with easy navigation capabilities. The current web site http://www.pharmatech.com will point to the new address at http://www.pharmatechoncology.com.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.


'/>"/>
SOURCE Pharmatech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
2. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
3. WuXi PharmaTech Announces Third Quarter 2008 Results
4. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
5. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
6. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
7. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
8. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
9. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
10. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
11. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):